Risk‐Stratified Surveillance for Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Comparison With the RETREAT‐Guided Surveillance Protocol
BACKGROUND: Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) is uncommon but associated with poor outcomes, requiring effective surveillance. We assessed adherence to and effectiveness of a risk-stratified surveillance protocol and compared it with the RETREAT-guided surveillance protocol. METHODS: We performed a single-center retrospective review of patients with HCC on explant after LT (2013-2023). Patients were assigned low- or high-risk surveillance based on explant pathology (AJCC tumor stage, grade, and vascular invasion). Protocol performance, modified surveillance strategies, and comparison with RETREAT across multiple cutoffs were assessed. RESULTS: Among 480 patients, 55 (11.5%) developed recurrence; 23 (41.8%) of these died, with median post-recurrence survival of 14 months. Only 15.8% were fully adherent, with higher adherence in low-risk patients (p<0.001). The protocol appropriately stratified risk (sensitivity 80.0%, specificity 54.1%) and retained substantially higher specificity than RETREAT even at RETREAT's conventional low-risk cutoff (32.0%) despite matching sensitivity; the two systems captured different patients (McNemar's test, p<0.001). Extrahepatic disease at recurrence was more common in high-risk patients (56.8% vs. 18.2%, p = 0.040). Fully adherent patients had earlier recurrence detection (206.4 vs. 666.9 days, p = 0.015). Modified protocols improved adherence but delayed some diagnoses; most low-risk recurrences occurred within 1 year and high-risk recurrences within 2 years. CONCLUSIONS: This protocol effectively stratifies recurrence risk and is more sensitive than the RETREAT-guided surveillance protocol. Modified strategies may improve adherence and reduce cost while maintaining effectiveness, particularly in low-risk patients.
Authors
- Emily A. Leven (ORCID: https://orcid.org/0000-0001-7508-5908)
- Maria Isabel Fiel (ORCID: https://orcid.org/0000-0002-7314-6313)
- Natalia Schmidt (ORCID: https://orcid.org/0009-0009-6342-7267)
- Lauren Tal Grinspan (ORCID: https://orcid.org/0000-0001-7455-280X)
- Thomas D. Schiano (ORCID: https://orcid.org/0000-0003-1878-5101)
- Pu Ni (ORCID: https://orcid.org/0000-0003-3278-093X)
- Haley Waite
- Marcelo E. Facciuto (ORCID: https://orcid.org/0000-0001-5919-5787)
- Ishaan P. Dharia (ORCID: https://orcid.org/0000-0001-5996-6377)
Institutions
- Mount Sinai Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1111/ctr.70685
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00